SCMP BusinessAI 繁中編譯23/9 10:00 (HKT)
分析師:美國加強審查臨床試驗 或威脅中國生物科技優勢
分析師指出，中國在快速且具成本效益的早期臨床試驗方面的優勢，助推其崛起成為全球生物製藥強國，但美國有可能採取措施遏制這一優勢。美國國會議員及食品及藥物管理局（FDA）官員
由 AI 自動翻譯自英文原文（保留香港新聞術語規範）
英文原標題：Rising US scrutiny on clinical trials could threaten China’s biotech advantage: analysts
英文原摘要：China’s edge in fast, cost-effective early clinical trials has propelled its emergence as a global biopharmaceutical powerhouse, but there is a risk that the United States could take steps to curb that advantage, according to analysts. US lawmakers and officials at the Food and Drug Administration (
HK24H 僅展示標題與短摘要（由 AI 編譯自英文），全文版權歸 SCMP Business 所有。